Glenmark Pharmaceuticals Inc. has announced the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in the United States, further expanding its injectable portfolio for the institutional healthcare segment.
The newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) manufactured by BPI Labs, LLC (NDA 205029). This approval allows Glenmark to offer a quality-assured generic alternative aligned with US regulatory standards.
According to IQVIA sales data, the Epinephrine Injection USP market recorded annual sales of approximately $67.6 million for the 12-month period ending October 2025, including both retail and non-retail channels. The data highlights the strong demand for epinephrine injections across hospital and emergency care settings in the US.
Commenting on the launch, Marc Kikuchi, President and Business Head, North America at Glenmark, said the company is focused on strengthening its institutional product portfolio while continuing to provide quality and affordable treatment options for patients. The addition of this product reinforces Glenmark’s long-term commitment to the US generics market.
Glenmark clarified that its Epinephrine Injection USP is approved only for the indications listed in its approved label and is not marketed for all reference listed drug indications. The market size cited includes the brand and all available therapeutic equivalents, based on IQVIA National Sales Perspectives data up to October 2025.